{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
benzyl benzoate
to a specific field?
Status:
Possibly Marketed Outside US
Source:
KLEER-PLEX ADVANCED ACNE CARE SYSTEM
Source URL:
First approved in 2007
Source:
21 CFR 358H
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Status:
Possibly Marketed Outside US
First approved in 1999
Source:
Dermal-Soothe by Vetoquinol USA, Inc.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Myristalkonium is used as spermicide in vaginal contraceptives. It has antiseptic properties also. Breastfeeding women might use it because it does not pass into maternal milk. Absorbed only on the surface of the walls of the vagina and then return to normal physiological droppings or eliminates simple washing with water. Adverse effects are: burning, itch, contact dermatitis. Any drug, introduced into the vagina, can inactivate the local spermicidal action of Myristalkonium.
Status:
Possibly Marketed Outside US
First approved in 1999
Source:
Dermal-Soothe by Vetoquinol USA, Inc.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Myristalkonium is used as spermicide in vaginal contraceptives. It has antiseptic properties also. Breastfeeding women might use it because it does not pass into maternal milk. Absorbed only on the surface of the walls of the vagina and then return to normal physiological droppings or eliminates simple washing with water. Adverse effects are: burning, itch, contact dermatitis. Any drug, introduced into the vagina, can inactivate the local spermicidal action of Myristalkonium.
Status:
Possibly Marketed Outside US
First approved in 1989
Source:
NADA140862
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Detomodine hydrochloride is a sedative with analgesic properties and α2-adrenergic agonist The dose-dependent sedative and analgesic effects reduce production of excitatory neurotransmitters, thereby calming the horse, relieving abdominal pain, and facilitating bronchoscopy and other procedures. Currently, detomidine is only licensed for use in horses.
Status:
Possibly Marketed Outside US
Source:
Finaplix®-H by Roussel-Uclaf
Source URL:
First approved in 1987
Source:
NADA138612
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Trenbolone is an anabolic steroid. It is used on livestock to increase muscle growth and appetite. Trenbolone compounds have a binding affinity for the androgen receptor three times as high as that of testosterone. Once metabolized, the drugs have the effect of increasing nitrogen uptake by muscles, leading to an increase in the rate of protein synthesis. It also has the secondary effects of stimulating appetite, reducing the amount of fat being deposited in the body, and decreasing the rate of catabolism. Short-term side effects include insomnia, high blood pressure, increased aggression, night sweats, and libido.
Status:
Possibly Marketed Outside US
Source:
Newton Homeopathics Food Allergy ~ Additives
Source URL:
First approved in 1956
Source:
21 CFR 341
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Status:
Possibly Marketed Outside US
First approved in 1953
Source:
NDA008708
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Erythrosine B (also known as Red No. 3), a Food and Drug Administration (FDA)-approved red food dye, is found in cosmetics and food. It is also used as a plasma stain for nerve cells and staining bacteria in soil. It was studied the modulating capabilities of erythrosine B on amyloid-beta peptide (Aβ) aggregation and Aβ-associated impaired neuronal cell function. It is known, that aggregation Aβ is closely linked to the development of Alzheimer's disease pathology.
Status:
Possibly Marketed Outside US
Source:
NCT00578890: Phase 4 Interventional Withdrawn Diabetic Foot
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Bendazac, (1-benzyl-1H-indazol-3-yl-oxy)-acetic acid, is structurally related to indomethacin. Its lysine salt has been reported to be absorbed better than the parent compound. It is applied topically as bendazac lysine 0.5% (wt/vol) aqueous solution for delaying the progression of cataract. Topical application of bendazac is associated with transient burning sensation. It reduces the secretion of the skin ulcer surface, promotes skin formation and accelerates tissue repair.
Status:
Possibly Marketed Outside US
Source:
Polivasal by Coli [Italy]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Suloctidil is considered to be calcium antagonist. In addition to its vascular antispasmodic activity, suloctidil affects blood platelets and enhances brain energy metabolism. Suloctidil was being evaluated in many clinical trials for use in dementia and thrombotic disorders. Suloctidil induces hepatotoxicity.
Status:
Possibly Marketed Outside US
Source:
NCT04270487: Phase 4 Interventional Completed Irritable Bowel Syndrome
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Otilonium is a musculotropic spasmolytic agent belonging to the family of quaternary ammonium derivatives and successfully used in the treatment of patients affected by Irritable bowel syndrome (IBS) due to its specific pharmacokinetic and pharmacodynamic properties. The positive polarity of the head of the Otilonium molecule determines the main pharmacokinetic property of this drug: a minimal systemic absorption and the consequently high safety profile. Studies on animal models revealed a specific Otilonium accumulation in colonic circular muscle at therapeutic µm concentrations, while its plasma levels were 1000 times lower, together with a poor penetration of the drug in the central nervous system. Consistently, after oral administration to healthy volunteers, the Otilonium plasmatic concentration was very low, less than 1% of the drug was eliminated by urine, and 97% was eliminated by feces. Recent clinical studies showed comparable safety and tolerability for Otilonium and placebo. Otilonium was shown to inhibit the main patterns of human sigmoid motility in vitro, including: the tone of smooth muscle cells (SMCs); the rhythmic phasic contractions induced by the interstitial cells of Cajal; and the strong contractions induced by stimulation of enteric motor neurons mainly by blocking the calcium influx through L-type calcium channels on SMCs. Recent in vitro studies using cultured human colonic SMCs to further assess the musculotropic spasmolytic properties of Otilonium confirmed that this drug causes smooth muscle relaxation through the inhibition of voltage-gated calcium channels (L-type > T-type) and the inhibition of muscarinic and tachykinergic effects.
